We are live on ! Find out more
KIN

Kindred Biosciences, Inc.
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

48 hedge funds and large institutions have $101M invested in Kindred Biosciences, Inc. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

94% more capital invested

Capital invested by funds: $52.4M → $101M (+$49.1M)

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

12% more funds holding

Funds holding: 4348 (+5)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $96K

Holders
48
Holders Change
+5
Holders Change %
+11.63%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
16
Reduced
13
Closed
3
Calls
Puts
$96K
Net Calls
-$96K
Net Calls Change
-$96K
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
+$44 +7 New

KIN Hedge Fund Activity: Q1 2017 in Review

48 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2017, worth a combined $101M — up 94% from $52.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KIN positions and 3 closed out — a net gain of 12 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was Park West Asset Management, adding an estimated $15M. The largest seller was Ariel Investments, cutting an estimated $6.04M.

  • 48 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2017, up from 43 in Q4 2016.
  • Funds reported $101M of Kindred Biosciences, Inc. stock for Q1 2017, up 94% quarter-over-quarter.
  • 15 funds opened new Kindred Biosciences, Inc. positions in Q1 2017 and 3 closed out, a net change of +12 holders.
  • The largest Kindred Biosciences, Inc. buyer in Q1 2017 was Park West Asset Management, an estimated $15M added.
  • The largest Kindred Biosciences, Inc. seller in Q1 2017 was Ariel Investments, an estimated $6.04M sold.

Based on aggregated 13F filings for Q1 2017.